US Food and Drug Administration (USFDA) has conducted a GMP inspection at Biocon's API manufacturing facility at Telangana from December 12 to 14, 2018. The inspection concluded without any observations and no Form 483 was issued. The successful inspection of this site reflects company's strong commitment to quality and cGMP compliance.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.